Health Canada has approved a combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer (NSCLC). The approval includes patients who have not received any form of systemic therapy for their metastatic disease and whose tumors contain no mutations in the EGFR or ALK genes. It also marks the first time that a dual immunotherapy regimen, given alongside a limited course of chemo,…
You must be logged in to read/download the full post.
The post Health Canada Approves Opdivo-Yervoy-Chemo Combo for Advanced NSCLC appeared first on BioNewsFeeds.